Özlem BİNGÖL ÖZAKPINAR, Aslı TÜRE, İlkay KÜÇÜKGÜZEL

Molecular modeling and assessment of cytotoxic andapoptotic potentials of imatinib analogues featuring(thio)urea motifs in human leukemia and lymphoma cells

Imatinib is a well-known anticancer drug. In this study, cytotoxic properties of thirty-two imatinib analogues featuring (thio)urea motifs have been evaluated against chronic myeloid leukemia (K562), Burkitt lymphoma(Raji) and mouse embryonic fibroblast (NIH 3T3) cells. IC50 values of selected eleven compounds were calculated against K562 and NIH 3T3 cells. Apoptotic properties of the most active three compounds were evaluated on K652 cells subsequently. Favorably, compounds 19, 31 and 32 induced early apoptotic changes on K562 cells. Loss of membrane potential as well as caspase-3 and caspase-9 activation was determined in the present study. Levels of anti-apoptotic proteins, Bcl-XL and Bcl-2 decreased after the implementation of compounds 19, 31 and 32 at 10 µM and 50 µM concentrations. To reveal further molecular insight into the anticancer activity of the compounds, compounds 19, 31and 32 were docked into ABL kinase protein as imatinib shows anticancer activity by inhibiting this enzyme. Modeling studies demonstrated significant molecular interactions between compounds 19, 31 and 32 and ABL protein.Compounds 19, 31 and 32 showed excellent superposition with imatinib in the binding site of ABL. These findings suggest that compounds 19, 31 and 32 have potential to show anticancer activity against chronic myeloid leukemia.

PDF

___

[1] WHO report on cancer: setting priorities, investing wisely and providing care for all. World Health Organization, 2020. License: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/handle/10665/330745, (accessed August 5, 2020).
[2] NIH National Cancer Institute. https://www.cancer.gov/types, (accessed August 5, 2020).
[3] Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol. 2017; 11(Suppl 5): 87. [CrossRef]
[4] Levitzki A. Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance. Annu Rev Pharmacol Toxicol. 2013; 53: 161-185.
[5] Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science. 2000; 289(5486): 1938-1942.
[6] Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019; 144: 19- 50. [CrossRef]
[7] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1): 57-70. [CrossRef]
[8] Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018; 17: 48. [CrossRef]
[9] Cui JJ. A new challenging and promising era of tyrosine kinase inhibitors. ACS Med Chem Lett. 2014; 5(4): 272-274. [CrossRef]
[10] Nowell PC. Discovery of the Philadelphia chromosome : a personal perspective. J Clin Invest. 2007; 17(8): 2033-2035.
[11] Türe A, Kahraman DC, Cetin-Atalay R, Helvacıoğlu S, Charehsaz M, Küçükgüzel İ. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors. Comput Biol Chem. 2019; 78: 227-241. [CrossRef]
[12] Türe A, Ergül M, Ergül M, Altun A, Küçükgüzel İ. Design, synthesis, and anticancer activity of novel 4- thiazolidinone-phenylaminopyrimidine hybrids. Mol Divers. 2020; 10.1007/s11030-020-10087-1. [CrossRef]
[13] Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995; 184(1): 39-51. [CrossRef]
[14] Boice A, Bouchier-Hayes L. Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res. 2020; 1867(6): 118688. [CrossRef]
[15] Fiskum G, Kowaltowksi AJ, Andreyev AY, Kushnareva YE, Starkov AA. Apoptosis-related activities measured with isolated mitochondria and digitonin-permeabilized cells. Methods Enzymol. 2000; 322: 222-234. [CrossRef]
[16] Stevens M, Oltean S. Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing. Front Genet. 2019; 10: 804. [CrossRef]
[17] Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27(20): 3312-3318. [CrossRef]
[18] Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012; 13(7): 1059-1067. [CrossRef]
[19] White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin Drug Discov. 2015; 10(4): 427-439. [CrossRef]
[20] Dietrich J, Hulme C, Hurley LH. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg Med Chem. 2010; 18(15): 5738-5748. [CrossRef]
[21] Shah P, Westwell AD. The role of fluorine in medicinal chemistry. J Enzyme Inhib Med Chem. 2007; 22(5): 527-540. [CrossRef]
[22] Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene. 2002; 21(56): 8541- 8546. [CrossRef]
[23] Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Onkogene. 1997; 15: 2333-2342.